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Randomized, Controlled Trials—
Reliving the Past. . .
We read with interest the VA CARDS (Veterans Affairs Coronary
Artery Revascularization in Diabetes) study (1) comparing percu-
taneous coronary intervention (PCI) and coronary artery bypass
grafting (CABG) in subjects with diabetes. In our opinion, the
most notable finding of the study is not the outcome of the trial,
but the actual study design itself, that is, the stringent
angiography- and clinically based inclusion and exclusion criteria,
which makes application of the study’s findings to real-world
contemporary clinical practice highly questionable. Notably, of the
6,678 diabetic patients screened for this study, a staggering
6,080/6,678 (91%) of screened subjects did not meet angiographic
requirements for the study, and only 198 subjects (3%) were
randomly assigned to either CABG (n  97, 1.5%) or PCI with
drug-eluting stents (DESs) (n  101, 1.5%) and completed the
2-year follow-up. Such a trial design is reminiscent of the PCI
versus CABG randomized trials undertaken before the SYNTAX
(Synergy Between PCI With Taxus and Cardiac Surgery) trial
(2,3), where “cherry-picking” of patients before randomization was
a major confounding issue (2% to 12% of screened patients were
randomized in most trials) that effectively invalidated the results of
these trials (4,5). The SYNTAX trial was designed to overcome
these limitations by incorporating an all-comers design in which
practically no patient was refused entry, with subjects either
randomized (if determined by the Heart Team to achieve “equiv-
alent anatomical revascularization” between CABG and PCI) or
nested in registries (2,3). This was at the insistence of 7 cardiac
surgeons (dubbed the “magnificent 7”) during the design of
SYNTAX to prevent selection bias, a view that was fully endorsed
by the clinical and interventional cardiologists at the time. To give
an example of the potential dangers of using highly selected
populations in a clinical trial design, a recent meta-analysis of
randomized trials undertaken before SYNTAX comparing PCI
with CABG (6) showed CABG to be favored in older subjects and
PCI to be favored in younger subjects, findings that have since
been directly contradicted by the all-comers SYNTAX trial (where
the opposite was shown) (7). In addition, the analyses demonstrat-
ing the anatomic SYNTAX score in the VA CARDS study not to
show any treatment effect between CABG and PCI warrant
specific mention in that they were severely underpowered to draw
any conclusions, even if considered hypothesis generating (8).
Specifically, the majority of subjects in the VA CARDS study had
low (22) (CABG: n  47 vs. PCI: n  59) SYNTAX scores,
with few subjects in the intermediate (23 to 32) (CABG: n  33
vs. PCI: n  24) or high (33) (CABG: n  13 vs. PCI: n  12)
SYNTAX scores, presumably due to the overwhelmingly restric-
tive angiographic inclusion and exclusion criteria of the study as
described earlier, thus making any comparisons of the low with the
higher SYNTAX score tertiles practically meaningless. Even
within the FREEDOM (Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Management of Mul-
tivessel Disease) trial, (9) analyses based on the SYNTAX score
tertiles appear to have been limited by power and were contra-
dicted by those reported in the pre-stratified and powered diabeticsubgroup of SYNTAX (10). The real lesson of the VA CARDS
study is that randomization of subjects in a clinical trial is not
enough and that an all-comers clinical trial design is warranted.
Anything less will take us back to the confusing era of randomized
trials performed before SYNTAX and will serve to cloud the
medical literature.
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Reply
In the letter about our paper (1), Drs. Farooq and Serruys make the
assertion that the VA CARDS (Veterans Affairs Coronary Artery
Revascularization in Diabetes) study is not applicable to contem-
porary coronary revascularization based on: 1) the angiographic
inclusion criteria being too strict; 2) the small percentage of
screened patients who were enrolled; and 3) that our study was
underpowered to evaluate SYNTAX (Synergy Between PCI With
Taxus and Cardiac Surgery) scores. The letter completely misses
important aspects of our study.
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known to have better survival with surgery than with medical
treatment. We deliberately excluded patients when the primary
role of revascularization would be symptom relief. These patients
were extensively studied in COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation) and
BARI 2D (Bypass versus Angioplasty Revascularization Interven-
tion 2 Diabetes) (2,3). Including these subsets would have in-
creased enrollment but also would have diluted the power of the
study to find survival differences.
Our screened patients included all patients with diabetes re-
ferred for a diagnostic angiogram for any reason. To compare
VA-CARDS to SYNTAX, we need to know the total number of
patients having diagnostic angiography at the 85 sites over their
2-year enrollment (4). An average of 500 diagnostic angiograms
per year per SYNTAX site would yield a total of 85,000 diagnostic
coronary angiograms. The 1,800 patients enrolled in SYNTAX
would then represent 2.1% of this total, which is lower than our
study.
Our study was not designed or powered to examine SYNTAX
score subgroups. The SYNTAX scores in our study merely show
that there was no systematic bias in the distribution of scores to
explain the observed survival difference. If anything, low SYNTAX
scores were more frequent for PCI than surgery. It is important to
note in this discussion that the SYNTAX trial itself was not
powered to compare small subgroups based on SYNTAX terciles.
There is no SYNTAX score that leads to an absolute improvement
in outcome for percutaneous coronary intervention over surgery
among patients with 3-vessel coronary disease. The failure to finda significant p value in the subanalysis of 352 patients with low
SYNTAX scores and 3-vessel coronary artery disease is likely to
represent a type II error (5). The SYNTAX investigators need to
report a power analysis of each of the subgroups that they analyze.
The assumption that the failure to find a difference means that
there is no difference is misleading.
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